Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Top Cited Papers
Open Access
- 15 April 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (15), 3109-3117
- https://doi.org/10.1182/blood-2009-04-214957
Abstract
Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, estKeywords
This publication has 32 references indexed in Scilit:
- Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokinesBlood, 2009
- JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficienciesSeminars in Cell & Developmental Biology, 2008
- Therapeutic targeting of Janus kinasesImmunological Reviews, 2008
- Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptorProceedings of the National Academy of Sciences, 2007
- Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617FPLOS ONE, 2006
- Loss of p53 impedes the antileukemic response to BCR-ABL inhibitionProceedings of the National Academy of Sciences, 2006
- The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationProceedings of the National Academy of Sciences, 2006
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Myelofibrosis with Myeloid MetaplasiaNew England Journal of Medicine, 2000